SCHEMBL30765737

SCHEMBL30765737

C[C@@H](Nc1cn(C)c(=O)n(CC(=O)O)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
MMP12 P39900 2/20 0.37
MMP13 P45452 2/20 0.37
NPY5R Q15761 1/20 0.37
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
RAB9A P51151 3/20 0.35
CYP2C9 P11712 2/20 0.35
NPC1 O15118 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
HPGD P15428 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PTGDR Q13258 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
GAA P10253 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HSP90AA1 P07900 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765712 0.87 LMNA (0.35) LMNAMMP12MMP13NPY5RUSP2
SCHEMBL30765588 0.85 MEN1 (0.42) LMNASMN1; SMN2HPGDNPSR1GAA
SCHEMBL30765619 0.81 LMNA (0.38) LMNAMMP12MMP13NPY5RUSP2
SCHEMBL31558435 0.80 ELANE (0.45) LMNAHDAC6
SCHEMBL30765814 0.80 LMNA (0.39) LMNAUSP2SMN1; SMN2CYP2C9CYP1A2
SCHEMBL31558409 0.78 POLB (0.36) LMNAMMP12MMP13NPY5RCYP2C9
SCHEMBL30765710 0.78 LMNA (0.38) LMNAMMP12MMP13USP2SMN1; SMN2
SCHEMBL30765863 0.78 GAA (0.38) LMNAMMP12MMP13NPY5RUSP2
SCHEMBL30765770 0.78 LMNA (0.38) LMNAMMP12MMP13USP2SMN1; SMN2
SCHEMBL30765867 0.78 HDAC6 (0.44) LMNAMMP12MMP13NPY5RUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed